

RESEARCH ARTICLE

Open Access

Prevalence and predictors of Lymphogranuloma venereum in a high risk population attending a STD outpatients clinic in Italy

Claudio Foschi¹, Antonella Marangoni^{1*}, Antonietta D'Antuono², Paola Nardini¹, Monica Compri¹, Sara Bellavista², Andrea Filippini², Maria Letizia Bacchi Reggiani³ and Roberto Cevenini¹

Abstract

Background: We evaluated LGV prevalence and predictors in a high risk population attending a STI Outpatients Clinic in the North of Italy.

Methods: A total of 108 patients (99 MSM and 9 women), with a history of unsafe anal sexual intercourses, were enrolled. Anorectal swabs and urine samples were tested for *Chlamydia trachomatis* (CT) DNA detection by Versant CT/GC DNA 1.0 Assay (Siemens Healthcare Diagnostics Terrytown, USA). RFLP analysis was used for CT molecular typing.

Results: L2 CT genotype was identified in 13/108 (12%) rectal swabs. All LGV cases were from MSM, declaring high-risk sexual behaviour and complaining anorectal symptoms. Patients first attending the STI Outpatient Clinic received a significant earlier LGV diagnosis than those first seeking care from general practitioners or gastroenterologists ($P = 0.0046$).

LGV prevalence and characteristics found in our population are in agreement with international reports. Statistical analysis showed that LGV positive patients were older ($P = 0.0008$) and presented more STIs ($P = 0.0023$) than LGV negative ones, in particular due to syphilis ($P < 0.001$), HIV ($P < 0.001$) and HBV ($P = 0.001$).

Multivariate logistic regression analysis revealed that HIV and syphilis infections are strong risk factors for LGV presence (respectively, $P = 0.001$ and $P = 0.010$).

Conclusions: Even if our results do not provide sufficient evidence to recommend routine screening of anorectal swabs in high-risk population, they strongly suggest to perform CT NAAT tests and genotyping on rectal specimens in presence of ulcerative proctitis in HIV and/or syphilis-positive MSM. In this context, CT DNA detection by Versant CT/GC DNA 1.0 Assay, followed by RFLP analysis for molecular typing demonstrated to be an excellent diagnostic algorithm for LGV identification.

Keywords: LGV, MSM, *Chlamydia trachomatis*, NAATs

Background

Lymphogranuloma venereum (LGV) is a systemic sexually transmitted infection caused by *Chlamydia trachomatis* (CT) serovars L1- L3 [1].

In 2003, a new outbreak of LGV proctitis was described in the Netherlands, mainly in men who have sex with men (MSM) [2], leading to an increase awareness for this disease throughout Europe.

The first Italian LGV case was observed in Milan in 2006 and only few cases of LGV proctitis have been described in Italy [3] so far.

In this study we assess LGV prevalence and predictors in a high-risk population attending a STI Outpatients Clinic of a University Hospital in the North of Italy.

Methods

Study population

From January 2012 to April 2013, all the patients attending the STI Outpatients Clinic of St. Orsola University Hospital of Bologna and reporting unsafe anal sexual intercourses

* Correspondence: antonella.marangoni@unibo.it

¹Microbiology, DIMES, University of Bologna, St. Orsola Hospital, Via Massarenti, 9, 40138 Bologna, Italy

Full list of author information is available at the end of the article

have been asked to carry out a clinical examination. An anorectal swab, a pharyngeal swab (if reporting oral sex intercourses) and an urine sample were collected from each patient for DNA detection of CT and *Neisseria gonorrhoeae* (GC).

Microbiological investigations for the main STDs (HIV, HCV, HBV and syphilis) and a serological screening for anti-*Chlamydia* antibodies by immunoenzymatic assays (Chlamydia IgG and Chlamydia IgA, Virion/Serion GmbH, Wurzburg, Germany) were performed in all patients. Diagnosis of genital warts was made by visual inspection. Furthermore, personal data and information about urogenital and rectal disorders, sexual behaviour, number of sexual partners in the last 6 months and history of previous STIs were recorded from each patient. Three months after antibiotic treatment for LGV, patients were re-evaluated.

A written consent was obtained by all the patients and the study protocol was reviewed by the Ethics committee of St. Orsola Hospital.

Diagnosis of CT infections and genotyping

Urine specimens, anorectal and pharyngeal swabs were processed by Versant CT/GC DNA 1.0 Assay (Siemens Healthcare Diagnostics, Terrytown, USA), a Real-Time PCR test simultaneously detecting the presence of CT and/or GC DNA [4]. In case of a CT positive result, molecular genotyping, based on *omp1* gene semi-nested PCR, followed by RFLP analysis was performed as previously described [5-7]. GC reactive results were confirmed by in-house PCR assay targeting *porA* pseudogene [8].

Statistical analysis

Analyses of the differences between the groups were performed with χ^2 test. Univariate and multiple logistic regression analyses were performed to evaluate the influence of the different variables on the outcomes. A *P* value <0.05 was considered significant. Statistical tests were performed using SPSS 13.0 for Windows computer software (SPSS, Chicago, Illinois).

Results

Patients characteristics

During the study period, a total of 108 patients met our admission criteria. In particular, 99 MSM (median age: 34.9; range 18–64 years) and 9 heterosexual women (median age: 35.8; range 19–52 years). Three of the women and 29 of the MSM complained about various rectal symptoms.

Diagnosis of CT infections and genotyping

Nineteen rectal swabs resulted positive only for CT and 10 only for GC, whereas 4 were simultaneously scored positive for CT and GC. Thanks to molecular genotyping, in 10 cases we found non-LGV serovars CT (6 E, 3D, 1 J),

while in 13 cases L2 serovar was identified, coming to the final diagnosis of LGV proctitis. The total prevalence of LGV infection was 12% (13/108).

Four urine samples were positive for non-LGV serovars CT, whereas 12 pharyngeal swabs and three urine specimens were positive for GC. No urine samples nor pharyngeal swabs were found positive for LGV-serovars CT. Finally, it is noteworthy to underline that in the high risk population of this study 38.3% of MSM (38/99) and 37.5% of the women (3/8) had at least one specimen scored CT or GC positive.

Detailed results are shown in Figure 1.

Clinical findings, risk factors and outcome of LGV cases

Based on rectal swab findings, patients with positive LGV results were defined as LGV-positive, while all the others (negative, non-LGV CT or GC cases) as LGV-negative.

All LGV cases were detected in MSM reporting unsafe receptive anal intercourses in the last 6 months.

In Table 1 statistical differences between LGV positive and LGV negative groups and logistic regression analysis to determine risk factors for LGV presence are presented in Table 2.

All patients suffering from LGV proctitis were symptomatic, complaining about anal pain (13/13), anal discharge (11/13), change in bowel habit (7/13), tenesmus (9/13) and inguinal adenopathy (5/13). In contrast, patients with non-LGV CT or GC proctitis were asymptomatic or complained about slight symptoms. In particular, only 30% CT and 40% GC positive patients were symptomatic respectively, in contrast to 100% LGV positive patients (*P* < 0.001).


When considering the mean age of LGV positive patients, we noticed a significant difference between LGV and non-LGV group (43 years vs. 34 years; *P* = 0.0008), as well as comparing LGV cases with non LGV-CT positive patients (43 years vs. 36 years; *P* = 0.04).

All LGV positive patients showed altered anti-*Chlamydia* IgG values, significantly higher than LGV-negative subjects (*P* < 0.001). Moreover, it is interesting to add that patients infected by non-LGV CT genotypes showed similar results to CT-negative patients (*P* = 0.102). Anti-*Chlamydia* IgA values were negative or only slight increased with no significant differences between studied groups.

All LGV positive patients but one suffered from other STIs; in particular, 9 were HIV-positive. Six of them were under HAART-therapy with a well control of the infection (viral load <1000 copies/ml; CD4 > 500 cells/ml).

When evaluating the distribution of other STIs in our population, we noticed that LGV positive patients presented more coinfections than LGV negative subjects (*P* = 0.001).

Finally, considering LGV cases, patients first attending the STI Outpatients Clinic (4/13) received an earlier



diagnosis compared to patients who first sought help from general practitioners or gastroenterologists. In particular, in the former group, time taken for LGV diagnosis was 2 weeks (range: 10–18 days), in contrast with the median of 8 weeks (4–92 weeks) of the latter group ($P = 0.0046$). First diagnostic hypothesis included inflammatory bowel diseases (IBD), enteritis and other STIs with rectal localization such as syphilis or gonorrhoea.

LGV positive patients were treated with doxycycline 100 mg twice a day for 3 weeks. They completely recovered after antibiotic therapy, regardless of their HIV status, HIV viral load or CD4 cell count.

Three months after treatment, rectal swabs and urine samples were negative both for CT and GC nucleic acids in all patients but one. This patient had a positive result for GC and a non-LGV serovar CT in his rectal swab, with recurrence of mild anal symptoms.

As expected, at follow-up visit anti-*Chlamydia* IgG antibodies values were similar to those found at the moment of LGV diagnosis.

Discussion

In the last decade, a new outbreak of LGV infection with rectal localization has been described in Europe, mainly

Table 1 Statistical analysis of the subjects by their LGV status

	LGV negative N = 95	LGV positive N = 13	P value
Reported symptoms % (n)	20% (19)	100% (13)	<0.001
MSM % (n)	91.6% (87)	100% (13)	0.601
Mean age (±SD), (range)	34 years (±9.5), (18–64)	43 years (±6.3), (27–53)	0.0008
Mean anti- <i>Chlamydia</i> IgG AU/ml, (range) [‡]	11.8 (4–38)	60.4 (19–86)	<0.001
Presence of coinfections [†] % (n)	47.3% (45)	92.3% (12)	0.0023
HIV % (n)	10.5% (10)	69.2% (9)	<0.001
Syphilis % (n)	16.8% (16)	69.2% (9)	<0.001
Gonorrhoea* % (n)	17.8% (17)	23.0% (3)	0.6519
Non-L serovar CT* % (n)	13.7% (13)	0% (0)	0.155
HBV % (n)	3.2% (3)	30.8% (4)	0.001
HCV % (n)	1.1% (1)	7.7% (1)	0.570
HPV warts % (n)	10.5% (10)	30.8% (4)	0.110

[†] A patient was considered coinfecting when at least one of the following infections was present: HIV, gonorrhoea, non-L CT, HBV, HCV, HPV warts.

*A patient was considered gonorrhoea or non-L CT positive when at least one of the site tested (pharyngeal swab and/or rectal swab and/or urine) resulted positive.

[‡] Normal values: IgG <15 Arbitrary Units/ml.

Table 2 Univariate and multivariate logistic regression analysis for LGV risk factors

	Univariate analysis		Multivariate analysis	
	OR (CI 95%)	P value	OR (CI 95%)	P value
Age (years)	1.11 (1.03-1.19)	0.003		
Presence of coinfections	13.33 (1.66-106.66)	0.014		
HIV	19.12 (4.96-73.61)	<0.001	12.64 (3.00-53.25)	0.001
Syphilis	11.10 (3.04-40.54)	<0.001	6.72 (1.58-28.45)	0.010
Gonorrhoea	1.37 (0.34-5.54)	0.653		
HBV	13.62 (2.62-70.68)	0.002		
HCV	7.8 (0.45-133.56)	0.155		
HPV warts	3.77 (0.98-14.54)	0.053		

in MSM [2]. International data about prevalence of LGV infection show considerable variability, depending on the characteristics of studied groups, with highest levels on high-risk selected population [9,10].

In our study, we found 13 cases of rectal LGV in a high-risk population and prevalence of LGV proctitis was 12%.

As shown in our investigation, LGV proctitis is usually symptomatic and it occurs as a moderate or severe ulcerative proctitis in more than 90% of cases [11], while non-LGV CT proctitis remains clinically silent in many cases [12].

In agreement with international literature [13-15], we observed that all LGV cases were diagnosed in MSM and that LGV positive patients were significantly older than LGV-negative ones ($P = 0.0008$).

Although patients reported active and passive anal intercourses, a LGV urethral infection has not been identified in our population. This is in concordance with previously reported studies [2,9] even if recently de Vrieze *et al.* found some cases of concurrent urethral LGV in a group of MSM with anorectal infection [16].

As observed in our cases, LGV proctitis can be easily misdiagnosed at the first investigations due to the unawareness of general practitioners and shame of patients in seeking care [11]. The most common misdiagnosis concerns IBD, since both endoscopic appearance of rectal mucosa and histological examination show similar characteristics [17].

High-risk sexual behaviours, including high number of sexual partners, unsafe intercourses, fisting and sex toys sharing are reported by most of LGV infected patients [18,19]. Common risk behaviours and LGV ulcerative lesions can both explain the high prevalence of other STIs found in LGV patients.

Our data highlighted a significant difference between LGV-positive and LGV-negative subjects regarding coinfections due to other STIs ($P = 0.0023$); in particular

among LGV patients higher rates of HIV ($P < 0.001$), syphilis ($P < 0.001$) and HBV ($P = 0.001$) infections were found. Logistic regression analysis in our population showed that HIV and syphilis represent the strongest risk factors for LGV infection ($P < 0.001$).

A strong association between anorectal LGV and HIV seropositivity has been already well documented [18], with rate of co-infection reaching 60-100% in MSM population [20].

It has been supposed that HIV-related immunodeficiency could delay LGV clearance [21]. Nevertheless, antibiotic treatment for LGV with doxycycline for 21 days appears to be equally effective both in HIV-negative and HIV positive patients [14].

As already observed [18], we confirm that LGV clinical presentation was not influenced by the use of HAART therapy and LGV outcome did not depend on HIV viral load or CD4 cell count.

Laboratory investigations have a crucial role in LGV diagnosis, but the quest for a reliable and simple method to discriminate between LGV and non-LGV CT infections is still going on. Both serological and nucleic acid amplification techniques (NAATs) indeed present critical issues.

Chlamydia serology can support LGV diagnosis in the appropriate clinical context, but the diagnostic utility of serological methods other than complement fixation and microimmunofluorescence procedures has not been well established yet [22,23]. In this study, we found a significant elevation of anti-*Chlamydia* IgG by an immunoenzymatic assay in LGV-positive patients, suggesting a potential role of IgG testing for LGV diagnosis.

On the other hand, NAATs have not been FDA cleared or CE marked yet on rectal specimens.

For that reason, many laboratories have performed their own validation studies in order to provide results for clinical management [22]. Moreover, since commercial NAATs can not differentiate LGV from non-LGV serovars, further investigations for CT molecular typing are needed. In the absence of specific LGV diagnostic testing, patients with a clinical syndrome consistent with LGV, should be treated with LGV regimen (doxycycline 100 mg orally twice a day for 21 days) [15,23].

In our experience, even if Versant CT/GC DNA 1.0 Assay has been not licensed for extragenital use, it showed good performances in CT/GC DNA detection on rectal and pharyngeal swabs. In addition, RFLP analysis of CT positive samples seems to be a reliable, inexpensive and time-saving method for CT genotyping.

It follows that our suggested algorithm (i.e. Versant CT/GC DNA 1.0 Assay and RFLP analysis of CT positive samples) could be an excellent choice for laboratory LGV diagnosis.

Even if our results do not provide sufficient evidence to recommend routine screening of anorectal swabs in MSM

population, they confirm, in agreement with European guidelines, the indication to perform CT NAAT tests and genotyping on rectal specimens in presence of ulcerative proctitis or in sexual contacts of LGV positive people [9,24].

In particular, our results suggest to test for rectal LGV all MSM complaining of anorectal symptoms, especially if other STIs (HIV and/or syphilis) are identified. Moreover, these subjects should be presumptively treated for LGV infection until CT molecular genotyping is known.

Conclusions

On the strength of our epidemiological and statistical results, testing for LGV infection should be recommended to all HIV and/or syphilis-positive MSM complaining of anorectal symptoms. For this purpose, CT DNA detection by Versant CT/GC DNA 1.0 Assay, followed by RFLP analysis for molecular typing demonstrated to be an excellent diagnostic algorithm for LGV identification.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

AM, AD, RC conceived and designed the study; CF, PN, MC, SB, AF performed the clinical visit and sample testing; CF, AM, LBR analyzed the data; CF, AM, RC wrote the paper; all authors read and approved the final manuscript.

Acknowledgments

We thank the nursing staff of the STD Outpatients Clinic and laboratory technologists of Microbiology Laboratory, St. Orsola University Hospital of Bologna for providing excellent support during this study.

Author details

¹Microbiology, DIMES, University of Bologna, St. Orsola Hospital, Via Massarenti, 9, 40138 Bologna, Italy. ²Dermatology, DIMES, University of Bologna, St. Orsola Hospital, Via Massarenti, 9, 40138 Bologna, Italy. ³Cardiology, DIMES, University of Bologna, St. Orsola Hospital, Via Massarenti, 9, 40138 Bologna, Italy.

Received: 28 January 2014 Accepted: 4 April 2014

Published: 9 April 2014

References

1. Sary G, Meyer T, Bangert C, Kohrgruber N, Gmeinhardt B, Kirnbauer R, Jantschitsch C, Rieger A, Sary A, Geusau A: **New chlamydia trachomatis L2 strains identified in a recent outbreak of lymphogranuloma venereum in Vienna, Austria.** *Sex Transm Dis* 2008, **35**:377–382.
2. Nieuwenhuis RF, Ossewaarde JM, Götz HM, Dees J, Thio HB, Thomeer HG, den Hollander JC, Neumann MH, van der Meijden WL: **Resurgence of lymphogranuloma venereum in Western Europe: an outbreak of chlamydia trachomatis serovar L2 proctitis in The Netherlands among men who have sex with men.** *Clin Infect Dis* 2004, **39**(Suppl 7):996–1003.
3. Cusini M, Boneschi V, Arancio L, Ramoni S, Venegoni L, Gaiani F, de Vries HJ: **Lymphogranuloma venereum: the Italian experience.** *Sex Transm Infect* 2009, **85**(Suppl 3):171–172.
4. Kerndt PR, Ferrero DV, Aynalem G, Monga D, Wang S, Zhang N, Wong C, Liggins M, Meng Q: **First report of performance of the versant CT/GC DANN 1.0 assay (kPCR) for detection of Chlamydia trachomatis and Neisseria gonorrhoeae.** *J Clin Microbiol* 2011, **49**(Suppl 4):1347–1353.
5. Lan J, Ossewaarde JM, Walboomers JM, Meijer CJ, van den Brule AJ: **Improved PCR sensitivity for direct genotyping of Chlamydia trachomatis serovars by using a nested PCR.** *J Clin Microbiol* 1994, **32**(Suppl 2):528–530.

6. Gallo Vaulet L, Entrocassi C, Corominas AI, Rodriguez Fermepin M: **Distribution study of Chlamydia trachomatis genotypes in symptomatic patients in Buenos Aires, Argentina: association between genotype E and neonatal conjunctivitis.** *BMC Res Notes* 2010, **3**:34.
7. Sayada C, Denamur E, Orfila J, Catalan F, Elion J: **Rapid genotyping of the Chlamydia trachomatis major outer membrane protein by the polymerase chain reaction.** *FEMS Microbiol Lett* 1991, **67**(Suppl 1):73–78.
8. Whitley DM, Buda PJ, Bayliss J, Cover L, Bates J, Sloots TP: **A new confirmatory Neisseria gonorrhoeae real-time PCR assay targeting the porA pseudogene.** *Eur J Clin Microbiol Infect Dis* 2004, **23**(Suppl 9):705–710.
9. Ward H, Alexander S, Carder C, Dean G, French P, Ivens D, Ling C, Paul J, Tong W, White J, Ison CA: **The prevalence of lymphogranuloma venereum infection in men who have sex with men: results of a multicentre case finding study.** *Sex Transm Infect* 2009, **85**(Suppl 3):173–175.
10. Defraye A, Van Beckhoven D, Sasse A: **Surveillance of sexually transmitted infections among persons living with HIV.** *Int J Public Health* 2011, **56**(Suppl 2):169–174.
11. Martin-Iguacel R, Libre JM, Nielsen H, Heras E, Matas L, Lugo R, Clotet B, Sirera G: **Lymphogranuloma venereum proctocolitis: a silent disease in men who have sex with men in industrialized countries.** *Eur J Clin Microbiol Infect Dis* 2010, **29**:917–925.
12. Hoentjen F, Rubin DT: **Infectious proctitis: when to suspect it is not inflammatory bowel disease.** *Dig Dis Sci* 2012, **57**(Suppl 2):269–273.
13. van der Laar MJ, Fenton KA, Ison C: **Update on the European lymphogranuloma venereum epidemic among men who have sex with men.** *Euro Surveill* 2005, **10**(Suppl 6), E050602.
14. White JA: **Manifestations and management of lymphogranuloma venereum.** *Curr Opin Infect Dis* 2009, **22**(Suppl 1):57–66.
15. European Centre for Disease Prevention and Control: **Sexually transmitted infections in Europe 2011.** Stockholm, Sweden: ECDC; 2013.
16. de Vrieze NH, van Rooijen M, Speksnijder AG, de Vries HJ: **Urethral lymphogranuloma venereum infections in men with anorectal lymphogranuloma venereum and their partners: the missing link in the current epidemic.** *Sex Transm Dis* 2013, **40**(Suppl 8):607–608.
17. Gallegos M, Bradley D, Jakate S, Keshavarzian A: **Lymphogranuloma venereum proctosigmoiditis is a mimicker of inflammatory bowel disease.** *World J Gastroenterol* 2012, **18**(Suppl 25):3317–3321.
18. Van der Bij AK, Spaargaren J, Morré SA, Fennema HS, Mindel A, Coutinho RA, de Vries HJ: **Diagnostic and clinical implications of anorectal lymphogranuloma venereum in men who have sex with men: a retrospective case-control study.** *Clin Infect Dis* 2006, **42**:186–194.
19. Ward H, Martin I, Macdonald N, Alexander S, Simms I, Fenton K, French P, Dean G, Ison C: **Lymphogranuloma venereum in the United Kingdom.** *Clin Infect Dis* 2007, **44**(Suppl 1):26–32.
20. Rönn MM, Ward H: **The association between Lymphogranuloma venereum and HIV among men who have sex with men: systematic review and meta-analysis.** *BMC Infect Dis* 2011, **11**:70.
21. van Nieuwkoop C, Gooskens J, Smit VT, Claas EC, van Hogezaand RA, Kroes AC, Kroon FP: **Lymphogranuloma venereum proctocolitis: mucosal T cell immunity of the rectum associated with chlamydial clearance and clinical recovery.** *Gut* 2007, **56**(Suppl 10):1476–1477.
22. By P, Papp JR, Schachter J, Gaydos CA, Van Der Pol B: **Recommendations for the Laboratory-Based Detection of Chlamydia trachomatis and Neisseria gonorrhoeae - 2014.** *MMWR Recomm Rep* 2014, **63**(RR-02):1–19.
23. Workowski KA, Berman S: **Sexually transmitted diseases treatment guidelines, 2010.** *MMWR Recomm Rep* 2010, **59**(RR-12):1–110.
24. de Vries HJ, Morré SA, White JA, Moi H: **European guideline of the management of lymphogranuloma venereum, 2010.** *Int J STD AIDS* 2010, **21**(Suppl 8):533–536.

doi:10.1186/1756-0500-7-225

Cite this article as: Foschi et al.: Prevalence and predictors of Lymphogranuloma venereum in a high risk population attending a STD outpatients clinic in Italy. *BMC Research Notes* 2014 **7**:225.